- Diagnostic value of CRP, PCT, NC and NLR in peripheral blood for bacterial infections in Non-small cell lung cancer patients after chemotherapy

CRP, PCT, NC and NLR in peripheral blood

  • Bin Wang Department of Thoracic Surgery, The 4th Centre Hospital of Nankai University, Tianjin 300000, China
  • Yanbin Wei Department of Pulmonary and Critical Care Medicine, Lishui Second People's Hospital, Lishui, Zhejiang 323000, China
DOI: https://doi.org/10.5937/jomb0-57772
Keywords: Non-small cell lung cancer; bacterial infections; CRP; PCT; NC; NLR

Abstract


Objective: We attempted to clarify and compare diagnostic value of CRP, PCT, NC and NLR in peripheral blood for bacterial infections of non-small cell lung cancer (NSCLC) patients after chemotherapy.

Methods: The 122 NSCLC patients under treatment in our hospital from October 2021 to October 2024 received selection as research cohort; among them, 50 NSCLC patients with bacterial infections after chemotherapy received selection as infection group and 50 NSCLC patients without bacterial infection after chemotherapy received selection as non-infection group. The general data, overall survival as well as CRP, PCT, NC and NLR levels in both groups received comparison.

Results: The CRP, PCT, NC and NLR levels in infection group demonstrated elevation in comparison to those in non-infection group (P < 0.05). The overall survival demonstrated no difference in infection group in comparison to that in non-infection group (P = 0.749). The AUC values of CRP, PCT, NC and NLR for diagnosing bacterial infections in NSCLC patients after chemotherapy received comparison, illustrating statistical significance (P < 0.05); among them, PCT had the highest AUC value of 1.000, and next was AUC value of NLR (0.981).

Conclusion: Application value of novel indicators such as PCT and NLR in diagnosing bacterial infections in advanced NSCLC patients after chemotherapy should be paid more attention to. The combination of the two may elevate efficacy of early diagnosis of bacterial infections.

References

1. Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli AM, Nepote A, et al. Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis. Semin Oncol. 2024.
2. Ali Salman R. Prevalence of women breast cancer. Cell Mol Biomed Rep. 2023;3(4):185-96.
3. Roy S. Membrane-associated RING ubiquitin ligase RNF-121 and advancement of cancer. Cell Mol Biomed Rep. 2025;5(2):80-90.
4. Zhao Q, Wang Y, Zou J, Kuang R, Ji S. MiR-146a alleviates acute lung injury via inhibiting Notch 1 signaling pathway targeting macrophage: MiR-146a alleviates acute lung injury. Cellular and Molecular Biology. 2024;70(1):34-9.
5. Robertson NM, Centner CS, Tejwani V, Hossen S, Karmali D, Lu S, et al. Preserved Ratio Impaired Spirometry (PRISm) Prevalence, Risk Factors, and Outcomes: A Systematic Review and Meta-Analysis. Chest. 2024.
6. Su Y, Luo P, Ni L, Hu J, Weng J, Shen E, et al. The clinical value of local consolidative therapy for oligo-residual disease in PD-1/PD-L1 inhibitors-treated non-small cell lung cancer. Front Immunol. 2024;15:1525236.
7. Nelli F, Ruggeri EM, Schirripa M, Virtuoso A, Giannarelli D, Raso A, et al. Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency. Curr Oncol. 2024;31(12):7647-62.
8. Yu X, Huang C, Du L, Wang C, Yang Y, Yu X, et al. Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial. EClinicalMedicine. 2025;79:102997.
9. Chen F, Zhang M, Yang F, Wang L, Liu J, Liu J, et al. Dual-Antigen-Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications. Small. 2024;20(17):e2307748.
10. Quartermain L, Buchan CA, Kilabuk E, Wheatley-Price P. Pulmonary Nocardiosis in a Non-Small Cell Lung Cancer Patient Being Treated for Pembrolizumab-Associated Pneumonitis. Case Rep Oncol. 2024;17(1):1222-8.
11. Zhang H, Yuan JF, Xu YY, Yang MJ, Lyu JL, Yang XJ, et al. Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors. Biomed Environ Sci. 2024;37(7):785-9.
12. Cohen SF, Cruiziat D, Naimer J, Cohen V, Kasymjanova G, Spatz A, et al. Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer. Curr Oncol. 2024;31(11):7379-89.
13. Reck M, Granados ALO, de Marinis F, Meyers O, Shen Q, Cho L, et al. Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab. Eur J Cancer. 2024;212:115050.
14. Vincent A, C AS. Predicting Severity of Acute Pancreatitis-Evaluation of Neutrophil-to-Lymphocyte Count Ratio as Emerging Biomarker: A Retrospective Analytical Study. Cureus. 2024;16(11):e74881.
15. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2017;15(4):504-35.
16. Yang L, Wang S, Zhou Y, Lai S, Xiao G, Gazdar A, et al. Evaluation of the 7(th) and 8(th) editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 2017;8(40):66784-95.
17. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes care. 2019;42(Suppl 1):S13-s28.
18. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Journal of hypertension. 2020;38(6):982-1004.
19. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2012;60(24):e44-e164.
20. Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos de bronconeumologia. 2017;53(3):128-49.
21. Guan Y, Cui Y, Gong Y, Liang X, Han X, Chen Y, et al. Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer. Sci Rep. 2024;14(1):32147.
22. Li Y, Jiang Y, Pan L, Yao J, Liang S, Du Y, et al. First-line chemoimmunotherapy for patients with small-cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis. Thorac Cancer. 2024;15(34):2437-48.
23. Mishra P, Faruqui T, Khanam S, Khubaib M, Ahmad I, Saeed M, et al. Sustainable synthesis of bakuchiol-mediated gold nanoparticles for drug delivery against bacterial strains and tumor microenvironments, and its in silico target proteins identification. Front Mol Biosci. 2024;11:1469107.
24. Ding S, Ma J, Song X, Dong X, Xie L, Song X, et al. Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy. J Oncol. 2020;2020:2192378.
25. Elkrief A, Méndez-Salazar EO, Maillou J, Vanderbilt CM, Gogia P, Desilets A, et al. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol. 2024;8(1):143.
26. Ma A, Wang G, Du Y, Guo W, Guo J, Hu Y, et al. The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer. Front Oncol. 2022;12:902955.
Published
2025/05/09
Issue
Vol. 44 No. 7 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Bin Wang, Yanbin Wei

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.